Answers are grounded in this paper and cite their sources.
Case report shows a novel translocation in therapy-related leukemia following high-risk neuroblastoma, suggesting new genetic insights.
Neuroblastoma is the most common extracranial malignancy of childhood. Patients with high-risk disease receive multimodal treatment including chemotherapy combinations containing alkylating agents and topoisomerase inhibitors with potential for inducing therapy-related malignancy later in life. Most commonly, cytogenetic changes of pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia involve chromosome 5 or 7. Here we report a novel case of therapy-related myelodysplastic syndrome/acute myeloid leukemia 30 months after treatment for high-risk neuroblastoma with biphenotypic cell surface markers and a not yet described translocation t(1;6)(q25;p23).
No takes yet. Share an insight, caveat, or question.
Whittle et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: